ABSTRACT Background: Low-grade chronic inflammation in overweight subjects is thought to play an important role in disease development. Objective: It was hypothesized that specific dietary components are able to reduce low-grade inflammation as well as metabolic and oxidative stress. Design: Dietary products [resveratrol, green tea extract, a-tocopherol, vitamin C, n23 (omega-3) polyunsaturated fatty acids, and tomato extract] selected for their evidence-based antiinflammatory properties were combined and given as supplements to 36 healthy overweight men with mildly elevated plasma C-reactive protein concentrations in a double-blind, placebo-controlled, crossover study with treatment periods of 5 wk. Inflammatory and oxidative stress defense markers were quantified in plasma and urine. Furthermore, 120 plasma proteins, 274 plasma metabolites (lipids, free fatty acids, and polar compounds), and the transcriptomes of peripheral blood mononuclear cells and adipose tissue were quantified. Results: Plasma adiponectin concentrations increased by 7%, whereas C-reactive protein (principal inflammation marker) was unchanged. However, a multitude of subtle changes were detected by an integrated analysis of the "omics" data, which indicated modulated inflammation of adipose tissue, improved endothelial function, affected oxidative stress, and increased liver fatty acid oxidation. Conclusion: An intervention with selected dietary products affected inflammatory processes, oxidative stress, and metabolism in humans, as shown by large-scale profiling of genes, proteins, and metabolites in plasma, urine, and adipose tissue. This trial was registered at clinical trials.gov as NCT00655798.
INTRODUCTION
The prevalence of overweight is increasing globally and has become a serious public health problem. Overweight increases the risk of chronic metabolic diseases such as type 2 diabetes and cardiovascular disease (1, 2) . Low-grade inflammatory status in overweight persons has been proposed as one of the mediating processes in metabolic disease development, such as cardiovascular diseases (CVDs) (3, 4) and diabetes (5) . Several studies support a link between oxidative stress and inflammation in atherogenesis (6, 7) .
Adipose tissue is crucial for the inflammatory status associated with obesity, primarily because of macrophage infiltration (8) . Adipocytes secrete both pro-and antiinflammatory adipokines, including proinflammatory tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), and the antiinflammatory adiponectin (9) (10) (11) . Reduced adiponectin (12, 13) and increased C-reactive protein (CRP) (5, 14) concentrations are associated with CVD and type 2 diabetes. The established inflammatory marker CRP originates from the liver.
A reduction in inflammatory status may prevent the occurrence of disorders and diseases related to overweight. Many food compounds have been reported to have antiinflammatory and/or antioxidant effects in various populations (15) . The Mediterranean diet contains several of these compounds and (16) has been associated with a reduction of CVD and type 2 diabetes (17) . Expressed in nutrients, this means high contents of antioxidant polyphenols, vitamins, long-chain unsaturated fatty acids, and carotenoids.
In the present study we aimed to investigate the antiinflammatory effects induced by nutritional intervention in overweight men with mildly increased CRP concentrations. Therefore, we selected potentially effective compounds aiming to cover a wide range of actions in the reduction of inflammation. We selected polyphenols from green tea (epigallocatechin gallate) and red wine (resveratrol), which reportedly have inhibitory effects on nuclear transcription factor jB (NF-jB) and activator protein 1 (AP-1) (18) . Resveratrol and omega-3 (n23) fatty acids are known for their inhibitory effects on cyclooxygenase 2. Antiinflammatory effects of n23 fatty acids have been shown by reduced plasma concentrations of CRP, TNF-a, and IL-6 (19) . Similarly, vitamin E intakes reduced plasma CRP and IL-6 concentrations in diabetic subjects (20) . In addition, vitamin E as well as tomato juice increased the lag time of LDL oxidation (20) . Hence, the "antiinflammatory dietary mix" (AIDM) consisted of fish oil, green tea extract, resveratrol, vitamin E, vitamin C, and tomato extract.
The effects of these dietary compounds were studied by using a nutrigenomics approach by large-scale profiling of genes, proteins, and metabolites in blood, urine, and fat tissue. We report the effects on markers of inflammation, oxidation, and metabolism by integrating the results from a multiplatform approach.
SUBJECTS AND METHODS

Study design
The study was a randomized, double-blind, placebo-controlled, crossover trial with 4 treatment periods of 5 wk each. Group size was based on power calculations by using a power of 80% and a 2-sided test with an a of 0.05 on the variables CRP and adiponectin. To show a difference of 1.4 mg/L for CRP, we needed a sample size of 32 subjects, which would enable detection of a difference of 0.4 mg/L for adiponectin. The study started with 36 subjects, allowing for some dropout. 
Subjects
Male subjects were selected from the pool of volunteers of TNO Quality of Life (Zeist, Netherlands) and recruited by advertisements and flyers. The men selected were generally healthy with a body mass index (BMI; in kg/m 2 ) between 25.5 and 35.0 and a low-grade inflammation determined on the basis of a CRP concentration of 1-10 mg/L. Subjects were excluded if they had a fasting blood glucose concentration of .6.9 mmol/L, fasting cholesterol concentration of .8 mmol/L, blood hemoglobin concentration of ,8 mmol/L, or high blood pressure [age ,55 y: diastolic blood pressure (DBP) .100 mm Hg or systolic blood pressure (SBP) .160 mm Hg; age 55-59 y: DBP .90 mm Hg or SBP .140 mm Hg]. Those with acute inflammation, as assessed on the basis of white blood cell count, were excluded. Furthermore, subjects with chronic diseases related to inflammation, using medication against blood clotting, with a medical history that might affect the study outcome, or using antiinflammatory medication were excluded. Additional exclusion criteria were as follows: food allergy, smoking, unexplained weight loss, consumption of .28 units of alcohol/wk, following a slimming diet, use of food supplements, and use of probioticcontaining products. Forty-three men were eligible and 42 were included, of whom 6 were appointed as a reserve and remained in the study until day 34. The baseline characteristics of the 36 men who completed the study are given in Table 1 .
Study products
The study products included AIDM capsules, 2 yogurts containing different probiotic strains, and a placebo treatment. This article focuses on the effects of AIDM; the effects of the yogurt treatments will be described in a separate paper (MJ van Erk, S Wopereis, GCM Bakker, et al, unpublished observations, 2010).
The subjects consumed 2 hard capsules and 2 soft capsules daily at breakfast with 200 mL plain yogurt (Chr Hansen, Hørsholm, Denmark) and at the evening meal. All doses were based on reported effects on inflammatory markers in humans and on tolerable levels (Dutch Health Council) and generally exceeded the regular recommended daily nutritional dose. Capsules consisted of a hard gelatin capsule (Microz Food Supplements, Geleen, Netherlands) containing 6.3 mg resveratrol (21) (daily dose equivalent to 4 L red wine), tomato extract containing 3.75 mg lycopene (20) (daily dose equivalent to 500 mL tomato juice), 94.5 mg green tea extract (40% epigallocatechin gallate; daily dose equivalent to 300 mL green tea) (22, 23) , 90.7 mg a-tocopherol (6) [Recommended Daily Intake (RDI): 18 IU; upper tolerable level: 1000 IU], and 125 mg vitamin C (upper tolerable level: 2000 mg/d) and a soft gel capsule containing 1200 mg cold water fish oil composed of 380 mg eicosapentaenoic acid (EPA), 260 mg docosahexaenoic acid (DHA) (24) , and 60 mg other n23 polyunsaturated fatty acids (Omega-3 "700"; Solgar Vitamin and Herb, Leonia, NJ) (RDI: 200 mg/d). Placebo hard and soft gel capsules contained 365 mg microcrystalline cellulose (Microz Food Supplements) and 1360 mg soy lecithin (soya lecithin; Solgar Vitamin and Herb), respectively.
Compliance was 99%, as assessed by evaluation of completed intake diaries and returned capsules. Compliance was supported by increased plasma concentrations of vitamin E after treatment with AIDM (mean increase: 83%; range: 42-134%).
Study procedures
The subjects were requested to maintain their habitual lifestyle and diet throughout the study, the use of nonsteroidal antiinflammatory agents was not allowed, and paracetamol use was limited. Furthermore, the subjects were not allowed to consume alcohol or to perform additional physical exercise on the last 2 d at the end of each treatment period. Study products provision and compliance checks were on a weekly basis. The subjects were instructed to fast overnight(from 2200)before each blood collection. On the last day of each treatment period, a fat-load test was performed. On the day before this test, the subjects started to collect their urine for a period of 24 h. On the next morning, the subjects consumed a standardized light breakfast (1597 kJ, 8.6% of energy as protein, 17.0% of energy as fat, and 72.4% of energy as carbohydrates) provided by TNO. After '4 h, they received a fat-load test consisting of a 500-mL milkshake containing high-fat dairy products supplying 46.1 g fat, of which 27.1 g was saturated fat (total energy content: 2945 kJ per serving). Within 6 h after consumption of the milkshake, 7 blood samples were collected at 0, 30, 60, 120, 180, 240, and 360 min. After dinner, a biopsy sample was obtained by a physician, who took subcutaneous fat from the abdomen for gene profiling.
Adverse events and medication use
Adverse events and medication use were classified according to ICD-10. No serious adverse events (AEs) occurred. In total, 80 and 100 AEs were reported by 28 of the 36 subjects when consuming the control mix and AIDM, respectively. The categories, intensity, and number of AEs were similar for both treatments. The predominant AEs were diarrhea and change in bowel habits. The most commonly used medications were overthe-counter drugs, of which antiinflammatory drugs, such as products based on acetylsalicylic acid, were used incidentally.
Blood and urine samples
EDTA-blood was used for the white blood cell count, differentiation, and CRP analysis. Sodium-citrate blood was used for the fibrinogen analyses and stored for additional analyses later on.
At week 4 of each treatment period, peripheral blood mononuclear cells (PBMCs) were isolated from EDTA-blood by using Leucosep tubes containing Ficoll Paque (Greiner, Alphen a/d Rijn, Netherlands) diluted with saline. Samples were centrifuged for 30 min at 800 · g at room temperature and PBMCs were collected, washed 2 times with saline, and divided over 4 aliquots, each containing '1 · 10 7 cells. Samples were stored for inhibitor-jB (I-jB), NF-jB, and AP-1 analyses and for isolation of RNA for gene profiling.
At week 5 of each treatment period, serum and EDTA-blood was collected for clinical chemistry tests and the measurement of a range of inflammatory and antioxidant markers, respectively. Serum clinical chemistry tests included the measurement of c-glutamyltransferase, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, glucose, insulin, total bilirubin, albumin, creatinine, urea, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, CRP, and fibrinogen were analyzed by using immunoturbidimetric techniques. Total cholesterol, HDL cholesterol, and triglycerides were measured with enzymatic techniques (Boehringer-Mannheim, Mannheim, Germany) on an Olympus AU400 clinical chemistry analyzer (Olympus-Diagnostica Europe, Hamburg, Germany). LDL cholesterol was calculated according to Friedewald et al (25) . Hematology variables were measured by using routine clinical techniques with an ADVIA 120 (Siemens Health Care Diagnostics, Deerfield, IL).
Inflammatory markers consisted of TNF-a, IL-6, IL-10, IL-12, IL-1b, IL-2, IL-4, IL-5, IL-7, IL-8, IL-13, interferon-c, and granulocyte-macrophage colony stimulating factor, all measured in plasma. The analyses were performed by using multiplex kits (high-sensitivity human cytokine premixed Lincoplex kit; Linco Research, St Charles, MO). In addition, plasma IL-17 and total adiponectin were analyzed by using enzyme-linked immunosorbent assay kits (Quantikine kit; R&D systems, Minneapolis, MN). The antioxidant markers 3-nitrotyrosine and troloxequivalent antioxidant activity (TEAC) were measured as described previously (26) . Indomethacin was added before plasma separation for prostaglandin E2 analyses (27) .
Blood samples for liquid chromatography-mass spectrometry (LC-MS) analysis of lipids and free fatty acids (FFAs) were collected after an overnight fast at the end of the 5-wk dietary intervention. Blood samples for the analysis of GC-MS and protein profiling were taken before and after the high fat load at regular intervals (0, 30, 60, 120, 180, 240, and 360 min.). These blood samples were collected into lithium-heparin tubes, and plasma was separated within 30 min at 4°C and stored at 270°C until analyzed. Aliquots of 24-h urine sample were used for the measurement of creatinine, 8-isoprostaglandin F 2 -a, and 8-hydroxy-2'-deoxyguanosine (26) .
Lipidomics and metabolomics
The LC-MS methods used for the measurement of plasma lipids and FFAs and the GC-MS method used for the measurement of a broad range of metabolites were identical to the methods reported by Wopereis et al (27) . The samples were analyzed in randomized order. For GC-MS, a total of 530 plasma samples were analyzed in 19 different batches. It was ensured that samples for one subject were analyzed within the same batch. Data for each subject were corrected for the recovery of the internal standard for injection. The performance of the applied metabolic profiling platforms was assessed through the frequent analysis of the quality control sample, and method performance was carefully monitored by using multiple internal standards (5-10 depending on the method, including analogs and 2 H-and 13 Clabeled metabolites), as described previously (28) . Batches were only accepted if the relative SD (RSD) of the peak area ratio for all internal standards was ,20%. Metabolites were only accepted if the RSD was ,20%, unless large differences between treatment groups were observed. Finally, the LC-MS FFA data set contained 21 metabolites: the LC-MS lipids data set consisted of 108 metabolites, and the GC-MS data set consisted of 145 metabolites (see Supplementary Table 2 under "Supplemental data" in the online issue). Also, 29 different metabolite ratios and sums were calculated (see Supplementary Table 3 under "Supplemental data" in the online issue). Metabolites were annotated by using an in-house metabolite database containing retention time information, MS spectra (electron impact ionization for GC-MS data), MS/MS spectra (LC-MS), and accurate mass data (LC-MS) of reference substances. The confidence of identification was 100%, unless indicated otherwise. Accurate MS and MS/MS data of reference substances and metabolites in the study samples were acquired by using Thermo LTQ-FT and Thermo LTQ-Orbitrap instruments (Thermo Fisher Scientific, Waltham, MA).
Proteomics
Plasma samples were sent to RulesBasedMedicine Inc (Austin, TX) for measurement of expression levels of 124 proteins (HumanMAP). Data were available for 33 subjects. The so-called 80% rule (29) was applied to retain only those proteins for which 80% of the values were above the detection limit for 1 of the 2 treatment groups, resulting in retention of 79 of the 124 variables. Values below the detection limit that remained in the truncated data set were replaced by a value of half of the detection limit. Values for remaining samples that were not measurable on the standard curve for a specific protein were set at 0.1 times the detection limit for that protein.
Transcriptomics
Total RNA was extracted from PBMCs and adipose tissue samples by using RNAzol (Campro Scientific, Veenendaal, Netherlands) and glass beads according to the manufacturer's instructions. RNA from adipose tissue samples was subjected to a clean-up step with the use of NucleoSpin columns (MachereyNagel, Germany).
The isolated RNA samples were sent to ServiceXS BV (Leiden, Netherlands) where they were processed according to Affymetrix protocols. In brief, RNA concentrations were measured by absorbency at 260 nm, and quality and integrity were verified with the RNA 6000 Nano assay on the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). In total, 134 RNA samples from PBMCs and 77 RNA samples from adipose tissue were of sufficient quality and subjected to array analysis.
The labeled cRNA, generated as described by Radonjic et al (30) , was further used for the hybridization to the NuGO Affymetrix Human Genechip NuGO_Hs1a520180 (30) . After an automated process of washing and staining, absolute values of expression were calculated from the scanned array by using Affymetrix GCOS software.
Quality control and normalization of microarray data were performed by using R/BioConductor packages through the NuGO pipeline that is available as a Genepattern procedure at http://nbx2.nugo.org (31) . One array from PBMC samples and 4 arrays from the adipose tissue samples did not pass quality control. As a result, data for 22 subjects were included in the intraindividual comparison of AIDM compared with placebo effects in adipose tissue and data for 32 subjects were included in the intraindividual comparison of AIDM compared with placebo effects in PBMCs.
Raw signal intensities were normalized by using the GCRMA algorithm. The custom CDF file for NuGO_Hs1a520180 (based on Entrez Gene, version 10.0.0; http://nugo-r.bioinformatics.nl/ NuGO_R.html) was used to re-annotate the probes to new probe sets, remove poor quality probes, and derive unique signal values for different probe sets representing the same gene (32) . This resulted in gene expression values for 16,242 genes with unique identifiers.
Transcriptome data sets for PBMCs and adipose tissue were analyzed separately. Genes were filtered on expression value .5 in 10 samples, resulting in a set of 10,812 genes for PBMCs and in a set of 11,283 genes for adipose tissue. Expression data were log transformed (base 2). Statistical analysis was performed in BRB ArrayTools (developed by Richard Simon and Amy Peng Lam; http://linus.nci.nih.gov/BRB-ArrayTools.html). In addition to a threshold for P values, a threshold was applied to fold change induced by intervention. Genes were used for biological interpretation and network construction if the P value was ,0.05 together with .20% up-regulation in 10 subjects or if the P value was ,0.05 together with .20% down-regulation in 10 subjects. Genomatix software tools (Genomatix GmbH, Munich, Germany) were used for transcription factor and biological network analysis. The microarray data have been submitted to ArrayExpress (http://www.ebi.ac.uk/microarray-as/ ae/; accession number E-TABM-871).
Statistical analysis
All data were analyzed for treatment differences by using analysis of variance (ANOVA). Data were first analyzed for a carryover effect of treatments between periods. Because this appeared not to be relevant, the ANOVA was simplified by not including this effect in further analyses. If the ANOVA indicated an overall treatment effect, comparisons between treatment means of the variables after AIDM and placebo intervention were performed by using a 2-sided (paired) Student's t test. Data were log transformed if necessary.
For LC-MS lipids and FFA data, a Tukey-Kramer adjustment was used to correct for multiple comparisons between treatments. The time curve of GC-MS and protein profiling data were analyzed on treatment differences by using a repeated-measures ANOVA. If a significant interaction between time and treatment was found, comparisons between treatment means of the variables were performed per time point by using a 2-sided (paired) Student's t test. If no significant interaction was found, main treatment effects averaged over time were investigated. Bonferroni adjustment was used to correct for multiple testing for GC-MS and protein profiling data.
In all statistical tests performed, the null hypothesis (no effect) was rejected at the 0.05 level of probability. The SAS statistical software package (versions 8.2 and 9.1; SAS Institute Inc, Cary, NC) was used for univariate statistical analysis.
For each significant metabolite, the mean treatment effect (expressed as change, in %) was calculated as follows:
where Xm is the mean treatment effect for metabolite m in the difference between AIDM and placebo (%), Ym is the mean intensity for metabolite m for placebo treatment, and Zm is the mean intensity for metabolite m for AIDM treatment. Gene expression data analysis is described in the paragraph above.
Biological interpretation
Functional analysis of the data were performed by using Ingenuity Pathway Analysis version 8.0 (Ingenuity Systems Inc, Redwood City, CA). This tool allows for simultaneous analysis of clinical chemistry, gene, protein, and metabolite data. To prevent domination of enrichment analysis by the gene expression data set, the analysis was performed both with and without the gene expression data.
Further information on the function and biological role of the variables was derived from MetaCore version 5. 
RESULTS
This study aimed to evaluate the effects of an AIDM in overweight men with mildly elevated CRP concentrations. The effects were characterized by measurement of established classic inflammation markers, such as CRP and adiponectin in combination with profiling of gene expression, proteins, and metabolites. Subjects maintained their habitual lifestyle, which was supported by unchanged body weight (99.9 6 10.6 kg for the placebo and 99.8 610.5 kg for the AIDM treatment) and blood pressure (SBP: 124 612 mm Hg for the placebo and 123 612 mm Hg for the AIDM treatment) after both treatment periods compared with their corresponding inclusion values ( Table 1) .
Overview of changes induced by AIDM
CRP and adiponectin were the main classic inflammation markers measured in this study. CRP concentrations did not change in response to the AIDM, whereas adiponectin concentrations increased significantly from 6.03 6 2.06 mg/L after placebo intervention to 6.48 6 2.57 mg/L after AIDM intervention (P , 0.05). The effects of the AIDM were investigated in more detail by large-scale analysis of gene expression, proteins, and metabolites in blood, urine, and adipose tissue biopsy samples. An overview of the numbers of measured variables that responded to the AIDM are shown in Table 2 . The supplementary tables show a detailed overview of all measured variables and the changes induced by the AIDM (see Supplementary Table 1 under "Supplemental data" in the online issue: multiplex analysis of proteins in plasma; see Supplementary Table 2 under "Supplemental data" in the online issue: analysis of metabolites in plasma; see Supplementary  Table 3 under "Supplemental data" in the online issue: plasma metabolite ratios and sums; see Supplementary Table 4 under "Supplemental data" in the online issue: significantly changed gene expressions in peripheral blood mononuclear cells; see Supplementary Table 5 under "Supplemental data" in the online issue: significantly changed gene expressions in adipose tissue biopsies; see Supplementary Table 6 under "Supplemental data" in the online issue: clinical chemistry variables in plasma and urine).
The complete set of significantly changed variables (Table 2 ) was subjected to functional enrichment analysis. The top 10 enriched biofunctions, shown in Figure 1A , confirm an effect of the AIDM on inflammation (inflammatory response, antigen presentation). Furthermore, the AIDM resulted in responses related to lipid metabolism and metabolic disease. The highest scoring network in the analysis without the gene expression data ( Figure 1B) illustrates the effects of the AIDM on inflammation (immune response), oxidative stress (production of reactive oxygen species), and lipid metabolism (quantity of lipid). The network indicates a central role for NF-jB in the effects of AIDM. A more detailed biological interpretation of the data focuses on these 3 processes: inflammation, oxidation, and metabolism.
Inflammation-related processes
The altered metabolites, proteins, and genes associated with inflammation, with mean percentage change in response to the AIDM, are shown in Table 3 . The metabolites, proteins, and genes are grouped in subprocesses, which are discussed below.
Eicosanoid-related inflammation
Metabolic profiling showed that the omega-3-omega-6 eicosanoid precursor ratio in plasma (EPA compared with AA; for details, see Supplementary Table 3 under "Supplemental data" in the online issue) was reduced, which indicated that the amounts of antiinflammatory eicosanoid precursors increased relative to the amounts of proinflammatory eicosanoid precursor (Table 3 ). In addition, many genes involved in prostaglandin metabolism were up-regulated in adipose tissue, namely PTGIS (prostaglandin I2 synthase), PGDS (prostaglandin D2 synthase), HPGD (hydroxyprostaglandin dehydrogenase), and PTGFRN (prostaglandin F2 receptor negative regulator).
Inflammatory mediators and signaling molecules
The plasma adiponectin concentration increased and the plasma prolactin concentration decreased in response to the AIDM. The antiinflammatory genes IL10RA (interleukin 10 receptor alpha) and SOCS3 (suppressor of cytokine signaling 3) were up-regulated in adipose tissue in response to the AIDM.
The plasma concentrations of the proinflammatory cytokine IL18 and chemokine (C-C motif) ligand 22 (CCL22), which may play a role in the trafficking of activated T lymphocytes to inflammatory sites, decreased. Also, the concentration of b 2 -microglobulin protein and the b-chain of major histocompatibility complex class I molecules decreased in plasma. Expression of the inflammatory gene IGHD (immunoglobulin heavy constant delta) increased in PBMCs in response to AIDM intervention, whereas gene expression of MYOM1 (myomesin 1), IGHV3-47 (immunoglobulin heavy variable 3-47), and IL12A (interleukin 12A) decreased. 1 GC-MS, gas chromatography-mass spectrometry; PBMCs, peripheral blood mononuclear cells.
2 Changed as a result of the antiinflammatory dietary mix (P , 0.05, ANOVA and/or paired Student's t test as described in Subjects and Methods), including Tukey-Kramer adjustment for lipids and free fatty acid data (n = 36 subjects), Bonferroni adjustment for GC-MS (n = 36 subjects) and protein data (n = 33 subjects), and a threshold of a 20% increase or decrease in 10 subjects for transcriptome data (n = 32 subjects for PBMCs, n = 22 subjects for adipose tissue). Clinical chemistry data were available for 36 subjects.
Plaque formation and coagulation
Plasma factor VII and TNF RII concentrations decreased, which are related to plaque formation and coagulation. In PBMCs, gene expression of VEGFB (growth factor for endothelial cells) increased, whereas that of PEAR1 (platelet endothelial aggregation receptor 1) decreased. Also, in adipose tissue, the expression of genes involved in plaque formation and coagulation changed. Expression of several platelet-related genes were down-regulated, including PF4 (platelet factor 4), NAPG (N-ethylmaleimide-sensitive factor attachment protein Top scoring network based on the functions and/or diseases that are most significant to the network objects (Ingenuity Pathway Analysis) in the analysis of the combined set of changed clinical chemistry markers, proteins, and metabolites. The biofunctions "immune response," "production of reactive oxygen species," and "quantity of lipid" are overlaid onto the network, showing which variables (nodes) are directly involved in these processes. Color coding of the nodes corresponds to the direction of responses (up-regulation shown in red and down-regulation shown in green). ADIPOQ, adiponectin; AFP, a-fetoprotein; APOA1, apolipoprotein A-I; APOC3, apolipoprotein C-III; CCL22, C-C motif chemokine ligand 22; CSF1, colony stimulating factor 1; F7, coagulation factor VII; FTH1, ferritin heavy polypeptide 1; ICAM1, intercellular adhesion molecule 1; IL1, interleukin-1; IL18, interleukin-18; IL12, interleukin-12; MPO, myeloperoxidase; TNFRSF1B, tumor necrosis factor receptor superfamily member 1B; VCAM1, vascular cell adhesion molecule 1; ifngamma, interferon c; MHC Class II, major histocompatibility class II. gamma), and PPBP (pro-platelet basic protein). Gene expression of a specific endothelial cell receptor (THBD), which ultimately reduces the amount of thrombin generated, was increased, as was the gene expression of PROCR (protein C receptor-endothelial). PROCR, PF4, and THBD are all part of the protein C pathway controlling blood coagulation.
Endothelial function
Plasma concentrations of intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) decreased. The gene expression of SMOC2 (SPARC related modular calcium binding 2), which is able to stimulate endothelial cell proliferation, increased in adipose tissue. Gene expression of ANGPTL5, which belongs to the angiopoietin family-an important growth factor specific for vascular endothelium-also increased in adipose tissue.
Blood cell differentiation
Two plasma proteins, 4 PBMC genes and 9 adipose tissue genes related to blood cell differentiation, responded to AIDM AT, adipose tissue; PBMCs, peripheral blood mononuclear cells; Pl, plasma; M, metabolomics; Pr, proteomics; T, transcriptomics; C, clinical data; PUFAs, polyunsaturated fatty acids; IL-18, interleukin-18; TNF RII, tumor necrosis factor receptor type 2; ICAM-1, intercellular adhesion molecule 1; VCAM-1, vascular cell adhesion molecule 1; CSF-1, macrophage colony stimulating factor 1; CCL-22, C-C motif chemokine 22 or monocyte chemotactic protein 1. All variables were significantly changed by the AIDM intervention (P , 0.05, ANOVA and/or paired Student's t test as described in Subjects and Methods), including Tukey-Kramer adjustment for lipids and free fatty acid data (n = 36 subjects), Bonferroni adjustment for gas chromatography-mass spectrometry (n = 36 subjects) and protein data (n = 33 subjects), and a threshold of a 20% increase or decrease in 10 subjects for transcriptome data (n = 32 subjects for PBMCs, n = 22 subjects for adipose tissue). Clinical chemistry data were available for 36 subjects.
2 Tissue refers to tissues in which a variable was measured. 3 Mean percentage change by AIDM. 4 Refers to supplementary tables; first digit corresponds to the supplementary table (1: proteins; 2: metabolites; 3: metabolite ratios or sums; 4: PBMC genes; 5: adipose tissue genes; 6: clinical data), and the second number (after the decimal point) corresponds to the row number in the supplementary table.
intervention. The gene expression of CCL21, which inhibits hemopoiesis and stimulates chemotaxis, decreased in PBMCs. Gene expression of TESC (tescalcin), a key factor in megakaryocytic differentiation, was down-regulated in adipose tissue. IL-15 is a cytokine that stimulates the proliferation of T lymphocytes, and its expression was up-regulated in adipose tissue. IL4R gene expression was up-regulated in PBMC. IL-4R can bind IL-4 to promote differentiation of T helper 2 cells and regulate immunoglobulin E production. Genes such as IL12A, IL7R, KLRG1 (killer cell lectin-like receptor subfamily G member 1), and NKTR (natural killer triggering receptor, all involved in activating T lymphocytes and natural killer cells, were down-regulated.
Oxidative stress-related processes
Concentrations of the oxidative stress marker 8-iso prostaglandin F2-a were reduced in urine, as were uric acid concentrations in plasma ( Table 4) . Plasma myeloperoxidase concentrations increased by 24%. A similar increase was observed for 2,3,4-triihydroxybutanoic acid (a degradation product of vitamin C) and indole-3-propionic acid. Elevated vitamin E concentrations are related to the presence of vitamin E in the AIDM. The plasma ferritin concentration was decreased and adipose tissue gene expression of HEPH (hephaestin) was increased, which are both involved in iron homeostasis. Expression of 2 genes encoding for mitochondrial proteins, NDUFS1
[NADH dehydrogenase (ubiquinone) Fe-S protein 1] and SLC25A27 (solute carrier family 25 member 27, also known as UCP4), were down-regulated in adipose tissue in response to AIDM. NDUFS1 is the core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase, and it is a ubiquinone iron-sulfur complex. SLC25A27 (UCP4), a member of mitochondrial uncoupling proteins, separates oxidative phosphorylation from ATP synthesis, whereby energy is dissipated as heat.
Metabolism-related processes
The AIDM had a profound effect on metabolism, specifically on lipoprotein metabolism. Concentrations of total cholesterol, LDL cholesterol, and HDL cholesterol increased and total triglyceride concentrations decreased in response to the AIDM. All affected metabolites, proteins, and genes involved in metabolism with mean percentage change in response to the AIDM are shown in Table 5 . Metabolites, proteins, and genes were grouped into different subprocesses, which are discussed below.
Lipoprotein metabolism
The AIDM intervention clearly affected lipoprotein metabolism at various levels (Table 5 ). In plasma, total triglycerides decreased by 5% and total diglycerides by 16%. Metabolic profiling (lipidomics) indicated significant changes, mainly occurring in medium and long chain triglycerides (50 or more C-atoms). Within this group of triglycerides; those with 0-4 double bonds decreased and those with 5 double bonds increased in response to the AIDM. Total plasma cholesterol increased by 5%, due to both plasma HDL (+5%) and LDL (+9%) cholesterol. The ratio of total cholesterol to HDL cholesterol remained unchanged. Of the increased individual cholesterol esters (Table 5 ), 85% could be attributed to cholesterol esters containing EPA (20:5) and 13% to DHA (C22:6) (see Supplementary Table 2 under "Supplemental data" in the online issue). Furthermore, the major protein component of HDL cholesterol, apolipoprotein A-I (apo A-I), increased, whereas the protein component for VLDL, apolipoprotein C-III (apo C-III), decreased. In adipose tissue, expression of genes involved in lipid transport were up-regulated, including cholesteryl ester transfer protein and fatty acid binding protein 3. In PBMCs, gene expression of LDL receptor and LRP5L (LDL receptor-related protein 5) and LRP12 were down-regulated, whereas gene expression of fatty acid transporter 1 (SLC27A1) was up-regulated. Expression of glycerol kinase, which phosphorylates glycerol, and diacylglycerol O-acyltransferase homolog 1 (DGAT1), which catalyzes the conversion of diglycerides to triglycerides, were increased in PBMCs.
Elongation and desaturation of fatty acids
Steroyl-CoA desaturase activity decreased in response to the AIDM, as indicated by the ratios of monounsaturated to saturated fat fromlipidssynthesizedinlivercontainingasinglefattyacid(ratiosof 16:0 and 18:0, see Supplementary Table 3 under "Supplemental data" in the online issue) and by down-regulated expression of the gene (SCD) in PBMCs. In addition, plasma d6 desaturase activity, as assessed by metabolite ratio (see Supplementary Table 3 under "Supplemental data" in the online issue), increased.
Plasma total elongase activity decreased and d6 desaturase activity increased in plasma, whereas gene expression of ELOVL7 AT 216 5.120 T 1 AT, adipose tissue; PBMCs, peripheral blood mononuclear cells; Pl, plasma; M, metabolomics; Pr, proteomics; T, transcriptomics; C, clinical data; U, urine. All variables were significantly changed by the AIDM intervention (P , 0.05, ANOVA and/or paired Student's t test as described in Subjects and Methods), including Tukey-Kramer adjustment for lipids and free fatty acid data (n = 36 subjects), Bonferroni adjustment for gas chromatography-mass spectrometry (n = 36 subjects) and protein data (n = 33 subjects), and a threshold of a 20% increase or decrease in 10 subjects for transcriptome data (n = 32 subjects for PBMCs, n = 22 subjects for adipose tissue). Clinical chemistry data were available for 36 subjects.
2 Tissue refers to tissues in which variables were measured. 3 Mean percentage change by AIDM. 4 Refers to supplementary tables; first digit corresponds to the supplementary table (1: proteins; 2: metabolites; 3: metabolite ratios or sums; 4: PBMC genes; 5: adipose tissue genes; 6: clinical data), and the second number (after the decimal point) corresponds to the row number in the supplementary table. (elongation of long-chain fatty acids family member 7) was upregulated in adipose tissue (Table 5) .
Amino acid metabolism
Plasma concentrations of total amino acids, branched-chain amino acids, and several individual amino acids and organic acids decreased, including alanine, proline, and phenylalanine (Table 5) .
Energy metabolism
Gene expression of ACACB (acetyl-coenzyme A carboxylase b, which is suggested to control fatty acid oxidation), ACOX1 (acyl-coenzyme A oxidase 1 palmitoyl, the first and rate-limiting enzyme in the peroxisomal fatty acid b-oxidation pathway), and DLST (dihydrolipoamide succinyltransferase, which catalyzes the oxidative decarboxylation of a-keto acids) all decreased in response to the AIDM in adipose tissue (Table 5 ). In line with decreased gene expression of DLST, the plasma a-ketoglutaric acid concentration decreased, whereas gene expression of L2HGDH (L-2-hydroxyglutarate dehydrogenase) in PBMCs, an enzyme that oxidizes L-2-hydroxyglutarate to a-ketoglutarate, increased. Gene expression of PANK1 (pantothenate kinase 1), an essential regulatory enzyme in CoA biosynthesis, was up-regulated in PBMCs. 
Glycemic control
Plasma 1,5-anhydro-D-glucitol and total glucagon-like peptide 1 decreased, which indicated a change in glycemic control (Table 5) . Moreover, gene expression of the transporter SLC37A4 was down-regulated in adipose tissue. This protein plays a central role in homeostatic regulation of blood glucose concentrations by transporting glucose-6-phosphate from the cytoplasm to the lumen of the endoplasmic reticulum.
Endocrine factors
Plasma concentrations of the hormones prolactin and glucagonlike peptide 1 decreased, whereas plasma concentrations of sex hormone-binding globulin and thyroxine-binding globulin increased (Table 5 ). Concentrations of testosterone and sex hormone-binding globulin were found to be lower in obese men (33) .
DISCUSSION
This study showed that supplementation with food components with evidence-based antiinflammatory properties modulated inflammation and oxidation and altered the metabolism status of healthy overweight subjects. These effects were detected by a nutrigenomics approach consisting of large-scale analysis of gene expression, proteins, and metabolites followed by integrated biological interpretation of these data generated on multiple "omics" platforms.
The main focus of the study was on inflammation, with adiponectin and CRP as established readouts. The plasma concentration of the antiinflammatory marker adiponectin increased in response to the AIDM. In contrast with unchanged concentrations of CRP, we detected numerous subtle changes in other markers related to inflammation, which together provided evidence of inflammatory modulation. In a similar study using a mild antiinflammatory drug, CRP concentrations in overweight men also remained unchanged (34) .
An effect on inflammation was anticipated because the food components were selected based on their antiinflammatory properties (6, (35) (36) (37) (38) (39) . Previously, we showed that a short-term intervention changed the expression of inflammatory genes in adipose tissue (40) . In the current study, most of the effects on inflammation (summarized in Figure 2 ) were also observed in adipose tissue, which is the critical site of the inflammatory state in obesity (8) . Our analyses did not suggest an antiinflammatory effect in the liver. However, we did not analyze liver tissue because samples are not easily collected, in contrast with PBMCs.
NF-jB and peroxisome proliferator-activated receptors (PPARs) are key regulators of obesity-associated inflammation (8, (41) (42) (43) . Transcription factor analysis of the adipocyte-related changes identified inflammatory markers, such as adiponectin and prolactin, as having binding sites for NF-jB and/or PPARc in their promoter region (Figure 3) . This suggests that NF-jB and PPARc are the regulators of antiinflammatory effects of AIDM in adipose tissue. Interestingly, the adiponectin gene was also found to have a binding site for transcription factor HNF4a, which we identified previously as a relevant transcription factor in adipose tissue (40) . Adiponectin is produced by adipose tissue and prolactin by both brain and adipose tissue (44, 45) . AIDM intervention increased adiponectin concentrations, whereas prolactin concentrations decreased. This corresponds to the notion that prolactin may reduce adiponectin production and secretion in adipose tissue (46) (47) (48) .
Plasma fatty acid ratios (specifically a decreased eicosanoid precursor ratio of n23 to n26) and gene expression in adipose tissue indicated an AIDM effect on eicosanoids, namely an inhibition of the synthesis of inflammation-related eicosanoids. Plasma prostaglandin E2 concentrations, however, did not change. The former observation is consistent with an antiinflammatory activity through inhibition of eicosanoid synthesis reported for resveratrol (49) , fish oil (36, 50) , and vitamin E (51) .
The data suggest a beneficial effect of AIDM on endothelial function and plaque formation. Lower concentrations of ICAM-1 and VCAM-1 indicate improvements in endothelial function, which may diminish atherosclerotic vascular disease risk in obesity (52) . Interestingly, supplementation of AIDM did result in decreased atherosclerosis in an atherosclerosis-prone mouse model (R Kleemann and T Kooistra, personal communication, 2008). Gene expression data in both human PBMCs and adipose tissue suggest altered blood cell differentiation, with indications of a lowering of natural killer cells, but not of macrophages (53, 54) . Resveratrol (49, 55) , lycopene (56) , green tea catechins (57) , and vitamin E (51) have been shown to ameliorate endothelial health and to reduce vascular inflammation and platelet aggregation.
AIDM also affected oxidative stress markers (summarized in Figure 4 ). Such an effect was anticipated, because antioxidant effects have been reported for multiple components of the AIDM: resveratrol (58), green tea catechins (59), lycopene (60) , vitamin E, and vitamin C. Potential reduction of oxidative stress by the AIDM is supported by decreased urinary concentrations of 8-isoprostaglandin F2-a, decreased plasma concentrations of uric acid, increased plasma concentrations of vitamin E, and increased plasma concentrations of the antioxidant indole-3-propionic acid. Indole-3-propionic acid is synthesized by gut microbiota (61) , which indicates an effect of AIDM in the gastrointestinal tract. The data also indicated an antioxidant effect in adipose tissue: myeloperoxide expression and 2,3,4-trihydroxybutanoic acid concentration both increased. Myeloperoxide may play a role in vitamin C degeneration into 2,3,4-trihydroxybutanoic acid (62) .
In addition, lipid metabolism was affected by AIDM (summarized in Figure 5 ), eg, plasma triglycerides decreased. The changes were most likely attributable to fish oil including EPA and DHA. These fatty acids activate PPARa (63), increase hepatic fatty acid oxidation, and reduce triglyceride synthesis, resulting in decreased plasma triglyceride concentrations (64) . The green tea catechins in AIDM may have contributed as well through the inhibition of intestinal lipid absorption (65) . Furthermore, PPARa activation is known to affect liver apolipoprotein synthesis; it increases apo A-I and decreases apo A-III (66) . Both changes may have contributed to the observed increases in HDL and LDL cholesterol. Apo A-I is an important component of HDL, and a reduction in apo C-III may result in the conversion of VLDL into smaller intermediate-densitylipoprotein and LDL particles (66) . Lipoprotein changes observed in this study together with changes in other established PPARa targets, such as d6 desaturase activity and SCD1 expression and activity (66) , correspond to an activation of PPARa. Earlier, we proposed that metabolic stress, together with inflammatory and oxidative stress, is one of the overarching processes whereby disbalance can lead to a range of diseases and homeostasis can be maintained by nutrition (67) . In obesity, metabolic stress can be defined as a disturbance of metabolic homeostasis as a result of caloric excess. Therefore, modulation of the overarching processes may be relevant for maintaining or ameliorating health.
Interestingly, some of the effects observed in our study may suggest effects of the AIDM in organs other than those directly analyzed, such as the brain. For instance, concentrations of prolactin, which is mainly synthesized in the brain, decrease after AIDM intervention. Prolactin is a well-established metabolic regulator that affects body weight regulation, pancreatic islet development, and other processes. Possible effects on the brain may support the association between increased intake of essential fatty acids (especially EPA and DHA), vitamin E, and vitamin C-all of which are present in the AIDM-and improved mental health (68) (69) (70) (71) . This findings may provide interesting leads for future research (72) .
Several limitations of this study need to be addressed. In this study, we used a specific combination of compounds in an effort to better mimic a real life situation, because a healthy diet consists of a mix of components. Choices for these compounds were mainly based on their individual antiinflammatory activities; a more optimal combination may exist. The mild effects observed may be attributed to the length of the intervention period. Also, it should be noted that, although we applied multiple platforms for large-scale screening of genes, proteins, and metabolites, it does not necessarily mean that we analyzed all variables of interest. This was because of limitations in the sampling of specific tissues and limitations in the analysis techniques, mainly on the protein and metabolite concentrations.
Despite these limitations, our approach allowed for the detection of multiple subtle health effects of a mix of dietary components in relatively healthy overweight subjects. Furthermore, the changes in concentrations of genes, proteins, and metabolite induced by the AIDM appeared to be consistent. This may prove to be an additional advantage of nutrigenomics technologies in human intervention studies, namely enabling the high-sensitivity detection of multiple physiologic changes.
In contrast with the accepted biomarkers, the application of nutrigenomics techniques for large-scale profiling of genes, proteins, and metabolites showed that the AIDM was able to influence processes of inflammation, oxidative stress, and metabolism in humans. The use of comprehensive techniques such as metabolic, protein, and gene profiling strongly facilitated the accurate and detailed quantification and description of the molecular processes involved.
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